Issue of Equity, Director Dealing & Voting Rights

Scancell Holdings Plc

15 October 2026

 

15 October 2026

Scancell Holdings plc

("Scancell" or the "Company")

Issue of Equity, Director Dealing and Total Voting Rights

Publication of Annual Report

Scancell Holdings plc (AIM: SCLP) a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announces that, further to the Circular posted to Shareholders on 2 October 2026, the Company has issued 7 ordinary shares of 0.1p each in the Company ("Ordinary Shares") to Dr Phil L'Huillier, Chief Executive Officer.

The 7 new Ordinary Shares have been issued in order to facilitate the proposed Share Consolidation of the Company's Existing Ordinary Shares on the basis of 10 Existing Ordinary Shares to 1 Consolidated Ordinary Share, and means the Company's issued share capital will be exactly divisible by 10. Further detail regarding the Share Consolidation can be found in the Circular.

Following the share issuance, Dr Phil L'Huillier holds 7 ordinary shares representing 0.00% of the company. 

Admission to Trading on AIM and Total Voting Rights

Application has been made for the 7 new Ordinary Shares to be admitted to trading on AIM, the admission of which it is expected on or around 16 October 2026.

In accordance with the provision of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Company confirms that, following the issue of the Shares, its issued ordinary share capital will comprise 1,212,230,690 ordinary shares.

All of the ordinary shares have equal voting rights and none of the ordinary shares are held in Treasury. The total number of voting rights in the Company will therefore be 1,212,230,690. The above figure may be used by shareholders as the denominator for the calculations to determine if they are required to notify their interests in, or change to their interest in, the Company.

Publication of Annual Report

The Company's annual report and financial statements for the year ended 30 April 2026 will be available today on the Company's website: https://scancell.co.uk/investors, and will be posted to shareholders along with notice of the 2026 AGM. A further announcement regarding posting and notice of the AGM will be made in due course.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Phil L'Huillier
2	Reason for the notification
a)	Position/status	CEO of the Company
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Scancell Holdings plc
b)	LEI	2138008RXEG856SNP666
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.1 pence each
b)	Identification Code	GB00B63D3314
c)	Nature of the transaction	Issuance of Ordinary Shares
d)	Price(s) and volume(s)	9 pence and 7 Ordinary Shares
e)	Aggregated information - Aggregated volume - Price	N/A
f)	Date of the transaction (s)	16 October 2026
g)	Place of the transaction	London Stock Exchange, AIM

Unless otherwise defined in this announcement, defined terms used have the meaning given to them in the Circular.

-ENDS-

For more information please contact:

Scancell Holdings plc Phil L'Huillier, CEO Jean-Michel Cossery, Chairman David Schilansky, CFO	[phone]
Panmure Liberum (Sole Placement Agent, Nominated Adviser and Joint Broker) Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	[phone]
WG Partners LLP (Joint Broker) Claes Spang	[phone]

Scancell (LSE:SCLP; www.scancell.co.uk) is a late-stage clinical biotechnology company developing targeted, off-the-shelf, active immunotherapies, generated by the ImmunoBody® and Moditope® platforms, designed to stimulate durable anti-tumor responses. The lead product, iSCIB1+, is a DNA ImmunoBody® that has demonstrated a favorable safety profile and clinically meaningful activity both as a monotherapy, in a Phase 1 trial, and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma. Modi-1 is a Moditope peptide currently being evaluated in a Phase 2 study in head & neck and renal cancers. In addition, Scancell is advancing a pipeline of high affinity GlyMab® antibodies targeting tumor specific glycans, two of which have been licensed for further development to Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.

 

END